Type I IL-1 Receptor (IL-1RI) as Potential New Therapeutic Target for Bronchial Asthma

Table 1

Effect of therapeutic experiments Targeting IL-1RI/IL-1 pathway.

Reagent	Mechanism	Animal model	airway hyperreactivity (AHR)	Inflammatory infiltration (eosinophils and lymphocytes)	IgE	Th1 cytokine	Th2 cytokine	Ref
Recombinant adenovirus expressing human IL-1ra (Ad-hIL-1ra)	receptor antagonist; gene therapy	Mice sensitized with ovalbumin (OVA)-immunized mice	$\downarrow$	$\downarrow$	N.A.	$\uparrow$ (IFN-$\gamma$)	$\downarrow$ (IL-5)	[34]
recombinant human interleukin-1 receptor antagonist (rhIL-1ra)	receptor antagonist	guinea pigs sensitized with Ascaris antigen	$\downarrow$ (pulmonary resistance)	$⟷$	N.A.	N.A.	N.A.	[35]
recombinant human interleukin-1 receptor antagonist (rhIL-1ra);	receptor antagonist	asthmatic guinea pigs sensitized with ovalbumin (OVA)-immunized mice	the asthmatic symptom was obviously attenuated	$\downarrow$ adhesionMolecules (sICAM-1 and P-selectin) levels	N.A.	N.A.	N.A.	[36]
antibodies against IL-1$\beta$	neutralizing monoclonal Ab	murine model of toluene diisocyanate-induced asthma	partial reduction	$\downarrow$ adhesionMolecules (ICAM-1 and VCAM-1) levels	N.A.	N.A.	$\downarrow$ (IL-4)	[37]